ANI Pharmaceuticals Cash Flow Statement
NASDAQ: ANIPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ANI Pharmaceuticals free cash flow
In fiscal 2025, ANI Pharmaceuticals generated $185.2 million of operating cash flow and spent $13.8 million on capital expenditures. That left free cash flow of $171.4 million, a free-cash-flow margin of 19.4% of revenue. Free cash flow was up 258.7% from the prior year's $47.8 million.
ANI Pharmaceuticals returned $13.4 million to shareholders: $1.2 million in dividends and $12.2 million in share repurchases, equal to 8% of free cash flow. Free cash flow covered dividend payments 148.1 times.
Summary generated from market data by MetaCap's automated system. Methodology
ANI Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 78.34M | -18.52M | 18.78M | -47.90M | -42.60M | -22.55M | 6.09M | 15.49M | -1.08M | 3.93M |
| Net Income growth (YoY) | — | -198.63% | — | — | — | -470.00% | -60.67% | — | -127.35% | -74.41% |
| Depreciation & Amortization | 91.42M | 67.73M | 59.79M | 56.97M | 47.25M | 44.64M | 44.61M | 33.74M | 27.93M | 22.34M |
| Stock-Based Compensation | 37.93M | 29.34M | 20.65M | 14.60M | 10.49M | 12.94M | 9.22M | 6.78M | 6.09M | 6.07M |
| Change in Working Capital | -49.34M | -41.90M | 5.07M | -55.50M | 7.84M | -28.72M | -9.91M | -1.66M | -6.89M | -23.89M |
| Operating Cash Flow | 185.22M | 64.02M | 118.96M | -31.20M | 3.32M | 15.27M | 45.63M | 67.07M | 39.42M | 27.47M |
| Capital Expenditures | -13.84M | -16.24M | -8.87M | -8.88M | -2.56M | -6.13M | -6.63M | -5.74M | -10.37M | -4.57M |
| Investing Cash Flow | -34.32M | -404.72M | -18.51M | -15.74M | -105.48M | -68.32M | -27.55M | -27.38M | -107.99M | -149.06M |
| Dividends Paid | -1.16M | -1.63M | -1.63M | -1.63M | -190.00K | 0 | 0 | — | — | — |
| Share Repurchases | -12.21M | -10.96M | -4.99M | -1.96M | -890.00K | -1.52M | -1.03M | 0 | 0 | -2.50M |
| Debt Issued | — | — | — | — | — | — | 0 | 0 | 75.00M | 0 |
| Debt Repaid | — | — | -3.00M | -3.00M | 0 | -8.03M | — | — | — | — |
| Financing Cash Flow | -9.94M | 264.94M | 67.44M | -5.13M | 194.59M | -1.44M | 1.25M | -27.82M | 72.36M | -729.00K |
| Net Change in Cash | 140.73M | -76.23M | 167.89M | -52.07M | 92.43M | -54.49M | 19.33M | 11.88M | 3.78M | -127.32M |
| Free Cash Flow | 171.39M | 47.78M | 110.09M | -40.08M | 765.00K | 9.13M | 39.00M | 61.33M | 29.05M | 22.91M |
This table shows 10 annual periods of ANI Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ANIP's reporting calendar. What is a cash flow statement?